Akums Drugs & Pharmaceuticals Ltd. Reports 14.8% Revenue Growth and 21% Adj EBITDA Growth in Q3 FY26
Akums Drugs & Pharmaceuticals Ltd., India’s Largest Contract Development and Manufacturing Organizations (CDMO), announced its financial results for the third quarter of FY26. Q3 FY 26 saw strong performance across its key business segments. CDMO saw a revenue growth of over 16% spurred on by double digit increase in volumes. The international branded formulation segment more than doubled sequentially led by demand recovery across its key markets. Adj EBITDA increased 21% YoY to Rs 147 cr as better capacity utilization along with a steady ramp up in the newer facilities led to margin improvement. Tighter control over overheads and portfolio rationalization helped mitigate losses in the API and Trade generics segment as well. The Company received European Union Good Manufacturing Practice (EU GMP) certification for two of its manufacturing facilities.
Key Highlights
- Revenue grew by 14.8% (Rs 1,160 crores in Q3 FY26 vs Rs 1,010 crores in Q3 FY25)
- Adjusted EBITDA increased by 21.0% (Rs 147 crores in Q3 FY26 vs Rs 121 crores in Q3 FY25)
- Adjusted PAT increased by 29.5% (Rs 86 crores in Q3 FY26 vs Rs 66 crores in Q3 FY25)
- Received EU GMP certifications for two manufacturing facilities
- Continued focus on operational excellence and disciplined growth